Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280.2 INR | +3.32% | +6.22% | +12.22% |
Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.22% | 3.88B | |
+2.49% | 96.73B | |
+0.61% | 21.31B | |
-16.61% | 21.21B | |
-5.38% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon : Launches Cancer Treatment Drug Everolimus in US